Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib Plus Pembrolizumab in Advanced Sarcoma
NCT04784247Phase 2Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Mar 2021
- Primary completion
- Mar 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lenvatinib, pembrolizumab in sarcoma, sponsored by Memorial Sloan Kettering Cancer Center. Started Mar 2021; status: active, not recruiting.
02
Drugs
lenvatinibpembrolizumab
03
Conditions
sarcoma
Beyond the preview
Go deeper on NCT04784247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04784247.